Trials / Completed
CompletedNCT02519062
Role of FDG PET, Immune and Hypoxic Marker in NSCLC
FDG-PET, Marker Immunologici ed Ipossici in Pazienti Affetti da Carcinoma Polmonare Non a Piccole Cellule in Stadio I-III Sottoposti a Chirurgia Radicale
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 130 (actual)
- Sponsor
- Istituto Clinico Humanitas · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a retrospective study that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of maximum 130 patients with NSCLC treated with surgery with radical intent at our center.
Detailed description
This is a retrospective observation that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of 130 patients with NSCLC treated with surgery with radical intent at our center. We will review FDG-PET acquired within 30 days prior to surgery and analyze its principal imaging characteristics with respect to hypoxic and immune-related markers at immunohistochemistry (IHC). These markers will be studied on tumor tissue obtained at surgery, used for diagnostic purposes and stored in paraffin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | This is a retrospective study |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2015-08-10
- Last updated
- 2020-10-01
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT02519062. Inclusion in this directory is not an endorsement.